These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 12548579)

  • 1. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
    Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.
    Pearse RN; Sordillo EM; Yaccoby S; Wong BR; Liau DF; Colman N; Michaeli J; Epstein J; Choi Y
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11581-6. PubMed ID: 11562486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
    Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
    J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
    Abu-Amer Y; Abbas S; Hirayama T
    J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
    Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
    Chikatsu N; Takeuchi Y; Tamura Y; Fukumoto S; Yano K; Tsuda E; Ogata E; Fujita T
    Biochem Biophys Res Commun; 2000 Jan; 267(2):632-7. PubMed ID: 10631114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
    Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
    Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
    J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.